Great announcement from BD1. This should drive the share price up a bit.
In my simple analysis, RHY which only focuses on colon cancer diagnostics has a market cap of $272M. BD1 produced outstanding results for ovarian and breast cancer diagnostic and currently sits at just over $200M market cap.
A simple googling will give the following information in terms of cancer market size they are targeting.
Colon cancer diagnostic market - 2B by 2023 (https://www.factmr.com)
Breast cancer diagnostic market - 6.3B by 2023 (https://www.researchandmarkets.com)
Ovarian cancer diagnostic market - 2.32B by 2027 (https://www.bccresearch.com)
The market that BD1 targets has at least 4x more opportunity. Comparing the two, I think BD1 could command around $10 a share.
Great announcement from BD1. This should drive the share price...
Add IIQ (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
56.5¢ |
Change
0.010(1.80%) |
Mkt cap ! $50.61M | |||
| Open | High | Low | Value | Volume |
| 55.0¢ | 56.5¢ | 54.0¢ | $124.9K | 227.0K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 10000 | 56.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 57.5¢ | 70 | 1 |
View Market Depth
| Last trade - 14.33pm 06/06/2024 (20 minute delay) ? |
|
|||||
|
Last
56.0¢ |
Change
0.010 ( 0.00 %) |
||||
| Open | High | Low | Volume | ||
| 55.0¢ | 56.0¢ | 54.5¢ | 14059 | ||
| Last updated 14.17pm 06/06/2024 ? | |||||
| IIQ (ASX) Chart |